BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Down 3.4% – Here’s What Happened

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) fell 3.4% during mid-day trading on Tuesday . The company traded as low as $7.65 and last traded at $7.66. 84,786 shares were traded during mid-day trading, a decline of 96% from the average session volume of 2,174,724 shares. The stock had previously closed at $7.93.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Needham & Company LLC upped their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a report on Monday. Barclays increased their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Finally, Evercore ISI lifted their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $15.17.

BioCryst Pharmaceuticals Stock Down 5.0 %

The business’s 50 day moving average is $7.60 and its two-hundred day moving average is $7.60. The firm has a market capitalization of $1.56 billion, a P/E ratio of -12.34 and a beta of 1.76.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.07). The company had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. During the same period in the prior year, the company posted ($0.19) earnings per share. The company’s revenue was up 35.1% on a year-over-year basis. As a group, equities analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current fiscal year.

Institutional Trading of BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of BCRX. Principal Financial Group Inc. grew its holdings in BioCryst Pharmaceuticals by 1,058.1% during the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock worth $3,127,000 after acquiring an additional 375,890 shares during the period. Exome Asset Management LLC acquired a new position in shares of BioCryst Pharmaceuticals in the 3rd quarter worth approximately $1,493,000. Franklin Resources Inc. raised its holdings in shares of BioCryst Pharmaceuticals by 177.8% in the 3rd quarter. Franklin Resources Inc. now owns 263,748 shares of the biotechnology company’s stock worth $1,968,000 after purchasing an additional 168,790 shares in the last quarter. Sanctuary Advisors LLC lifted its stake in BioCryst Pharmaceuticals by 78.3% during the third quarter. Sanctuary Advisors LLC now owns 47,389 shares of the biotechnology company’s stock valued at $360,000 after purchasing an additional 20,818 shares during the last quarter. Finally, SkyView Investment Advisors LLC boosted its holdings in BioCryst Pharmaceuticals by 30.0% during the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock worth $99,000 after buying an additional 3,000 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.